Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863798 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
NCT00863798: Completed Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00863798 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 682 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00863798, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.
Primary Outcome
HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.
Interventions
- DRUG placebo
- DRUG Desvenlafaxine Succinate Sustained-Release 10mg
- DRUG Desvenlafaxine Succinate Sustained-Release 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00863798 record still lists
NCT00863798 is an interventional study that assigns participants to a tested intervention. The registered 682 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00863798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00863798 about?
NCT00863798 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder". The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of l...
What is the current status of trial NCT00863798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2009-04. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00863798?
The interventions under investigation include: placebo (DRUG), Desvenlafaxine Succinate Sustained-Release 10mg (DRUG), Desvenlafaxine Succinate Sustained-Release 50 mg (DRUG).
Who is sponsoring clinical trial NCT00863798?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00863798's enrollment target sits among peer trials
682 529th of 2000 higher than 1,471 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05382559 · 681 participants · Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
- NCT06795087 · 684 participants
Discharge Medication Use Post-Operatively in GU Cancer Patients
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia